Cathie Wood's ARK Invest has recently adjusted its portfolio by purchasing shares of CRISPR Therapeutics while divesting from Teradyne and Roku. This strategic move indicates ARK's positive outlook on the potential of CRISPR technology, highlighting the firm's focus on innovative investments. The decision to sell holdings in Teradyne and Roku suggests a reallocation of resources towards sectors ARK believes have stronger growth prospects. By acquiring CRISPR stock, ARK demonstrates confidence in the advancements and future opportunities within gene-editing technologies. These transactions reflect ARK's ongoing commitment to investing in cutting-edge industries. The shift also underscores the dynamic nature of ARK's investment strategy, which adapts to emerging trends and technologies. Overall, the changes in ARK's portfolio emphasize its belief in the transformative potential of CRISPR Therapeutics.